Zanubrutinib is under clinical development by BeiGene and currently in Phase II for Lupus Nephritis. According to GlobalData, Phase II drugs for Lupus Nephritis have a 50% phase transition success ...

Felzartamab is under clinical development by Biogen and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition success rate ...

Palleon Pharmaceuticals and Shanghai Henlius Biotech have entered a licence agreement and partnership for the former’s ...

In a new study published in Lupus Science & Medicine, researchers explored the efficacy of using a combination of belimumab and standard immunotherapy compared to standard immunotherapy alone in ...

The lupus nephritis market is poised for growth, driven by rising disease prevalence, advancements in therapeutics such as biologics and targeted therapies, and increased investment in R&D.

ACR 2024 highlighted new guidelines for the screening, treatment, and management of lupus nephritis, stressing prompt kidney biopsy and timely treatment.

Request a sample and discover the recent advances in lupus nephritis treatment drugs @ Lupus Nephritis Pipeline Report The lupus nephritis pipeline report provides detailed profiles of pipeline ...

DelveInsight's lupus nephritis pipeline report depicts a robust space with 30+ active players working to develop 35+ pipeline therapies for lupus nephritis treatment. Key lupus nephritis companies ...